ADIM
LMAT icon

Alpha DNA Investment Management’s LeMaitre Vascular LMAT Stock Holding History

Alpha DNA Investment Management’s Portfolio LMAT Stock Details LMAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-5,257
Closed -$488K – 230
2024
Q3 		$488K Sell
5,257
-812
-13% -$70.4K 0.18% 118
2024
Q2 		$499K Buy
+6,069
New +$446K 0.19% 104
2023
Q4 		– Sell
-9,475
Closed -$516K – 213
2023
Q3 		$516K Buy
+9,475
New +$562K 0.21% 135

Other funds holding LMAT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CCA
Conestoga Capital Advisors Wayne, Pennsylvania $5.01B AUM 6.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCM
Copeland Capital Management Conshohocken, Pennsylvania $4.5B AUM 18.67% 1-Year Est. Return
GCM
Geneva Capital Management Milwaukee, Wisconsin $4.71B AUM 6.32% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
RIM
Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Alpha DNA Investment Management's LMAT Position: Q4 2024 in Review

Alpha DNA Investment Management sold out of LeMaitre Vascular (LMAT) in Q4 2024, closing a stake of 5,257 shares — an estimated $488K sold.

Alpha DNA Investment Management first reported a position in LMAT in Q3 2023 and held it in 3 quarters. The position peaked at $516K in Q3 2023. 307 funds tracked by Wall St. Rank hold LMAT as of Q4 2024.

  • Alpha DNA Investment Management reported no remaining LeMaitre Vascular position as of Q4 2024 after selling out during the quarter.
  • Alpha DNA Investment Management sold 5,257 LeMaitre Vascular shares in Q4 2024, an estimated $488K.
  • Alpha DNA Investment Management first reported a position in LeMaitre Vascular in Q3 2023 and held it in 3 quarters.
  • Alpha DNA Investment Management's LeMaitre Vascular position peaked at $516K in Q3 2023.
  • 307 funds tracked by Wall St. Rank held LeMaitre Vascular as of Q4 2024.

Based on Alpha DNA Investment Management's 13F filing for Q4 2024, filed 13 Feb 2025.